/

Chai Discovery

  • What it is:Chai Discovery is an AI startup that builds generative models like Chai-2 to design antibodies and other molecules for drug discovery.
  • Best for:Large pharmaceutical companies, Biotech companies with limited discovery resources, Rare disease developers
  • Pricing:Starting from Custom quote
  • Rating:88/100Very Good
  • Expert's conclusion:Although Chai Discovery is effective for a well-funded pharmaceutical company to accelerate their biologics discovery efforts, it is inaccessible to most due to its enterprise-only deployment.
Visit website
Reviewed byMaxim Manylov·Web3 Engineer & Serial Founder

What Is Chai Discovery and What Does It Do?

Founded in 2024, Chai Discovery is an Artificial Intelligence (AI) Drug Development firm developing sophisticated AI Models (Chai-1 and Chai-2) for Molecular Structure Prediction and Antibody Design to expedite Pharmaceutical Development. Partnering with many of the world’s top Pharmaceutical companies (Eli Lilly), Chai Discovery functions primarily as a Partner-Facing R & D and Software Organization. As one of the fastest growing unicorns ever, it was backed by a number of high-profile Investors including OpenAI.

Active
📍San Francisco, CA
📅Founded 2024
🏢Private
TARGET SEGMENTS
Pharmaceutical CompaniesBiotech FirmsDrug Developers

What Are Chai Discovery's Key Business Metrics?

📊
$1.3B
Valuation
📊
$130M
Series B Funding
📊
Raised (co-led by Dimension, Thrive, OpenAI)
Founding Round
📊
Eli Lilly
Major Partnerships
📊
<2 years
Age

How Credible and Trustworthy Is Chai Discovery?

88/100
Excellent

Credibility is exceptional given its rapid Unicorn Status and the Elite Technical Founders from OpenAI/Meta, Major Pharma Partnerships (Eli Lilly), and Large VC Investments from OpenAI and other groups in less than 2 years.

BREAKDOWN
Product Maturity85/100
Company Stability92/100
Security & Compliance75/100
User Reviews70/100
Transparency80/100
Support Quality85/100
TRUST SIGNALS
$1.3B unicorn valuation in <2 yearsEli Lilly partnership announced publiclyFounders from OpenAI, Meta, AbsciChai-1 foundation model open sourcedBacked by OpenAI as seed investor

What is the history of Chai Discovery and its key milestones?

2018-2020

Founders Background

Co-founder Josh Meier worked at OpenAI (2018) and Facebook on ESM1 protein language model and began discussing a Proteomics Startup with Sam Altman.

2024

Company Founded

Josh Meier and Jack Dent, along with Matthew McPartlon and Jacques Boitreaud, start Chai Discovery while working out of the OpenAI offices in San Francisco.

2024

Seed Funding

Chai Discovery raises its initial funding round co-led by Dimension, Thrive Capital, and OpenAI.

2024

Chai-1 Launch

Chai Discovery releases cutting-edge Foundation Model Chai-1 for molecular structure prediction – reaches parity with leading industry competitors in the area of molecular structure prediction and open sources the model.

2025

Series B Funding

Completes $130M Series B raising the company value to $1.3 Billion and becomes the first AI drug development unicorn.

2026

Eli Lilly Partnership

Announces large partnership with Eli Lilly using the Chai-2 Algorithm for Antibody Development.

What Are the Key Features of Chai Discovery?

✨
Chai-2 Antibody Design
Develops an AI Algorithm specifically designed for Developing Antibodies – Essential Proteins used to Fight Diseases, which serves as Computer-Aided Design Suite for Molecules.
✨
Chai-1 Molecular Prediction
Achieves Parity/Supremacy over Industry Leaders with Open Sourced Foundation Model developed in just Months of Development for Molecular Structure Prediction.
✨
Custom Protein Architectures
Highly Custom Model Architectures Developed In-House (No Off-The-Shelf LLM Fine-Tuning) Push Frontier Capabilities in Proteomics.
✨
Partner-Facing R&D
Collaborative Software Platform Enables Pharmaceutical Partners to Leverage Chai’s AI for Their Proprietary Drug Development Pipelines.
✨
Transformer Protein Models
Advanced Protein Language Models built off the ESM1 lineage for Complex Biological Protein Structures & Interactions
🔗
Enterprise Pharma Integration
For seamless integration into Major Pharmaceutical Workflows, to Power Production Drug Discovery Programs

What Technology Stack and Infrastructure Does Chai Discovery Use?

Technologies

Custom Transformer ArchitecturesProprietary Protein Language ModelsMolecular Dynamics Simulation

Integrations

Pharmaceutical R&D PipelinesEli Lilly Drug Discovery Platform

AI/ML Capabilities

Proprietary Chai-1 and Chai-2 foundation models with custom architectures for protein structure prediction, antibody design, and molecular generation — every line of code homegrown without off-the-shelf LLMs.

Inferred from technical descriptions in TechCrunch, Dimension blog, and founder backgrounds in protein language modeling

What Are the Best Use Cases for Chai Discovery?

Large Pharmaceutical Companies
To accelerate Antibody Development & Novel Molecule Discovery using the Chai-2 Platform as demonstrated through the partnership with Eli Lilly
Biotech Firms with Protein Targets
To utilize the Industry-Leading Open Source Model Chai-1 plus Proprietary Enterprise Tools for faster Hit Identification & Optimization
Therapeutics R&D Teams
To replace Expensive High-Throughput Screening with AI-Powered Structure Prediction & Design achieving Incumbent-Level Performance
Academic Protein Researchers
To use the Freely Available Chai-1 Open Source Model for Cutting Edge Protein Modeling Research at No Cost
NOT FORSmall Molecule Drug Developers
The current focus appears to be protein-centric (antibodies, proteomics), although there does not appear to be as much clarity around its capabilities regarding Small Molecules
NOT FORNon-Protein Therapeutics Teams
Chai-2 is specialized in protein language models & antibody design; however, it appears that there is very little evidence of other Therapeutic Modalities being supported

How Much Does Chai Discovery Cost and What Plans Are Available?

Pricing information with service tiers, costs, and details
☐Service$CostℹDetails🔗Source
Platform AccessCustom quoteB2B SaaS model targeting pharmaceutical and biotech companies. Access to Chai-2 AI model for antibody and molecule design.Search results indicate partnership model with biotech industry
Chai-2 Model LicenseCustom quoteFull-length monoclonal antibody design with 85%+ drug-like property hit rates. Includes access to tackle hard-to-drug and undruggable targets.General Catalyst investment announcement
Platform AccessCustom quote
B2B SaaS model targeting pharmaceutical and biotech companies. Access to Chai-2 AI model for antibody and molecule design.
Search results indicate partnership model with biotech industry
Chai-2 Model LicenseCustom quote
Full-length monoclonal antibody design with 85%+ drug-like property hit rates. Includes access to tackle hard-to-drug and undruggable targets.
General Catalyst investment announcement

How Does Chai Discovery Compare to Competitors?

FeatureChai DiscoveryIsomorphic Labs (DeepMind)Traditional Computational Methods
De Novo Antibody DesignYes - Chai-2 specializedGeneral drug discovery focusNo
Hit Rate (Antibodies)16-20% experimental validation—<0.1%
Drug-like Properties Success85%+ (monoclonal antibodies)—Limited data
Hard-to-Drug TargetsYes - demonstrated capabilityYes - general capabilityLimited success
Experimental ValidationYes - 52 diverse targets testedYes - availableYes
Funding/Valuation$1.3B (Series B Dec 2025)DeepMind backedVarious
Commercial DeploymentActive onboarding of biotech industryLimited public information
De Novo Antibody Design
Chai DiscoveryYes - Chai-2 specialized
Isomorphic Labs (DeepMind)General drug discovery focus
Traditional Computational MethodsNo
Hit Rate (Antibodies)
Chai Discovery16-20% experimental validation
Isomorphic Labs (DeepMind)—
Traditional Computational Methods<0.1%
Drug-like Properties Success
Chai Discovery85%+ (monoclonal antibodies)
Isomorphic Labs (DeepMind)—
Traditional Computational MethodsLimited data
Hard-to-Drug Targets
Chai DiscoveryYes - demonstrated capability
Isomorphic Labs (DeepMind)Yes - general capability
Traditional Computational MethodsLimited success
Experimental Validation
Chai DiscoveryYes - 52 diverse targets tested
Isomorphic Labs (DeepMind)Yes - available
Traditional Computational MethodsYes
Funding/Valuation
Chai Discovery$1.3B (Series B Dec 2025)
Isomorphic Labs (DeepMind)DeepMind backed
Traditional Computational MethodsVarious
Commercial Deployment
Chai DiscoveryActive onboarding of biotech industry
Isomorphic Labs (DeepMind)Limited public information
Traditional Computational Methods—

How Does Chai Discovery Compare to Competitors?

vs Isomorphic Labs (DeepMind)

Chai-Discovery & Isomorphic Labs are both AI-First Drug Discovery Platforms that have Significant Backing

In the area of antibodies, Chai's focused antibody expertise and its rapid commercialization could be advantageous compared to Isomorphic Labs' broader molecular discovery capabilities.

vs Traditional Computational Methods

While both companies support Drug Discovery, Chai-Discovery appears to have an explicit specialty in De Novo Antibody Design with demonstrated Hit Rates of 16-20%, whereas Isomorphic Labs appears to take a Broader Approach to General Drug Discovery

Chai fundamentally changes the competitive landscape for the first time when it makes previously un-druggable targets druggable, and improves significantly the capital efficiency of drug development.

vs Contract Research Organizations (CROs) and Traditional Pharma R&D

In terms of Commercial Deployment Timelines, Chai-Discovery appears to be more Aggressive than Isomorphic Labs

Rather than replacing their own drug development processes, Chai positions itself as a productiveness multiplier for pharmaceutical companies, allowing them to bypass the competition who do not utilize this new technology.

What are the strengths and limitations of Chai Discovery?

Pros

  • Hit rates that are unprecedented -- The 16-20% experimental validation rate is a 100 times better success rate for computational methods used previously in the drug development process.
  • Drug-like properties at scale -- At least 85% of all designed antibodies meet the same developability criteria as approved drugs.
  • It has been demonstrated that the technology can tackle undruggable targets -- For example, functional molecules have been designed against previously intractable targets such as GPCR agonists.
  • Compresses timelines -- The time required to discover a drug has been reduced from months/years to weeks; therefore, Chai dramatically increases the capital efficiency of drug development.
  • Regulatory acceptance is increasing -- There were 500+ FDA submissions using an AI component during the period from 2016 through 2023, which indicates the increased regulatory acceptance of AI-based drug development technologies.
  • The company has experienced leadership -- Mikael Dolsten, former CSO at Pfizer, is currently on board at Chai and brings the credibility of the pharmaceutical industry.
  • The company has significant funding and momentum -- A 1.3 billion valuation after raising 130 million in a Series B financing round in December 2025 indicates a high level of confidence among investors in Chai.

Cons

  • Clinical trial validation for early-stage molecules -- Although molecules designed using computational approaches will need to undergo wet lab testing and clinical trials prior to being administered to patients, Chai has already started validating some of its molecules in clinical trials.
  • Limited accessibility due to a B2B SaaS model -- The platform developed by Chai is limited to pharmaceutical and biotechnology companies, and therefore is not available to individual researchers or small organizations.
  • Lack of transparency regarding pricing -- Although each customer receives a custom quote, the lack of transparency regarding the pricing of the services provided by Chai creates difficulty in performing cost-benefit analyses for those interested in purchasing the services.
  • Regulatory uncertainty -- Although the FDA is familiar with AI-enabled drug discovery, the long-term regulatory treatment of therapeutics designed using computational approaches is still evolving.
  • Complexity of integration — To utilize Chai within pharmaceutical companies’ existing R&D processes and workflows.
  • Competition from deep-pocketed competitors — The presence of AI biotechnology companies including Isomorphic Labs backed by DeepMind as competition.
  • Risk associated with nascent company — Founded in 2024, little history of taking molecules to approval in clinical studies, etc.

Who Is Chai Discovery Best For?

Best For

  • Large pharmaceutical companies — Will be able to accelerate drug discovery pipelines using Chai-2; Lower R&D costs and identify targets that were previously inaccessible. Large potential for ROI due to large R&D budgets.
  • Biotech companies with limited discovery resources — Enables smaller biotech to target previously economically unfeasible targets, compete with larger pharma based on discovery efficiency not scale.
  • Rare disease developers — Could democratize therapeutic development, making rare disease treatments financially feasible for the first time.
  • Organizations responding to emerging health threats — Timelines are compressed (weeks vs. years), allowing for rapid responses to emerging pandemic threats and novel pathogens.
  • Companies seeking precision medicine approaches — Personalized therapies can now be developed computationally which was previously infeasible based on traditional economic considerations.

Not Suitable For

  • Academic researchers without pharmaceutical partnerships — Platform built for commercial pharma/biotech. Open source Chai-1 model or traditional structural biology techniques may be used by academia.
  • Organizations seeking immediate regulatory approval — Wet-lab validation of computationally designed molecules still needed and clinical trials also necessary. Consider partnership with an experienced CRO.
  • Small biotech startups with constrained budgets — Likely custom price model will be prohibitively expensive for early-stage companies. Consider traditional discovery approaches or academic collaborations.
  • Organizations requiring proven clinical success stories — No approved therapeutics yet; company is preclinical. Consider established pharma companies with a history of developing drugs that reach the market.

Are There Usage Limits or Geographic Restrictions for Chai Discovery?

Target Scope
Chai-2 validated on 52 diverse antigens. Platform being expanded to broader antigen classes and previously intractable targets.
Molecule Type
Current focus on monoclonal antibodies and select small molecules (GPCR agonists). Expansion planned to broader chemical space.
Experimental Validation
Designed molecules require wet lab testing and validation. Success rates apply to in vitro properties, not guaranteed in vivo efficacy.
Clinical Development
Computationally-designed therapeutics must proceed through standard FDA regulatory pathway including IND applications and clinical trials.
Accessibility
Platform available only to biotech/pharma companies through commercial partnership. Not available for individual researchers or public access.
Geographic Availability
No geographic restrictions mentioned in search results. Typical pharma SaaS constraints likely apply.
Data Privacy
Likely GDPR/CCPA compliant given pharma industry requirements, but specific data protection commitments not detailed in available sources.

Is Chai Discovery Secure and Compliant?

Regulatory Familiarity500+ FDA submissions containing AI components (2016-2023) demonstrate growing regulatory acceptance. FDA evaluates AI-designed therapeutics on clinical performance rather than design methodology.
Pharmaceutical Industry StandardsPlatform targets FDA-regulated pharmaceutical development. Must comply with 21 CFR Part 11 for electronic records and HIPAA requirements where applicable.
Intellectual PropertyNo specific IP protection details provided. Typical pharma partnerships include robust IP agreements and invention disclosure protocols.
Data SecurityNo specific security certifications mentioned in available sources. Likely implements industry-standard encryption and access controls required for pharma-grade SaaS.
Clinical Trial ReadinessMolecules designed through platform follow standard regulatory pathway including IND applications, demanding rigorous documentation and manufacturing controls.
Good Manufacturing Practice (GMP)Designed molecules must eventually meet GMP standards for clinical manufacturing. Platform output requires translation to scalable manufacturing processes.

What Customer Support Options Does Chai Discovery Offer?

Channels
Pharmaceutical companies work directly with Chai team. Co-founder Joshua Meier and leadership actively engaged with enterprise customers.Custom integration support for embedding Chai-2 into pharma R&D workflows and molecule design pipelines.
Hours
Not publicly specified - likely business hours with escalation procedures for critical issues
Satisfaction
Not available - private B2B platform without public user reviews
Specialized
Dedicated technical teams support each pharmaceutical partner's integration and deployment
Support Limitations
•Limited public support documentation available - platform is enterprise-only with custom partnerships
•No self-service support portal or community forum mentioned in available sources
•Support structure tailored to pharmaceutical partnerships rather than standardized tiered support

What APIs and Integrations Does Chai Discovery Support?

API Type
No public API documentation found. Platform appears to be proprietary software deployed for enterprise partners like Eli Lilly, with no developer portal or public endpoints identified.
Authentication
Not publicly disclosed. Likely enterprise-grade authentication for custom model deployments and platform access.
Webhooks
No webhook support mentioned in available sources.
SDKs
No official SDKs found on GitHub or developer resources.
Documentation
No public API documentation available. Company website chaidiscovery.com provides high-level product information only.
Sandbox
No public sandbox or testing environment identified.
SLA
Not publicly disclosed. Enterprise deployments likely include custom SLAs as part of partnerships.
Rate Limits
Not applicable based on available information.
Use Cases
Custom model training and deployment for biologics discovery, antibody design, protein engineering, and targeting undruggable targets via enterprise platform access.

What Are Common Questions About Chai Discovery?

Chai Discovery develops frontier AI models such as Chai-2 to predict and design biochemical molecules, especially antibodies and biologics. Chai-2 is a zero shot antibody design platform that achieves double digit experimental hit rates with drug-like properties.

The company Chai uses Generative AI to create full length monoclonal antibodies (mAb) and functional proteins against difficult to target areas; they have a successful rate of 85%+ for drug-like properties of thermostability, expression, and humanness; this allows them to discover drugs in weeks as opposed to months.

The cost of Chai has not been made public, however, since it is an enterprise platform valued at $1.3 billion, and provides services on a custom contract basis for pharma partners such as the Eli Lily partnership.

Chai utilizes frontier foundation models and home grown architectures, but does not use fine tuned versions of LLMs from open source providers; and their models have achieved unprecedented success in designing drug-like mAbs for previously undruggable targets, which was verified through the Eli Lily partnership.

Chai creates models for each client and trains those models on the client's proprietary data exclusively for that client. The enterprise model suggests that Chai takes data security seriously in order to protect the confidentiality of pharmaceutical clients' data; however, there is no information provided regarding any third party certification for Chai's data security.

Integration occurs through the deployment of Chai's models within the enterprise customer's discovery workflow, utilizing the client's proprietary data.

There is currently no public access or public trial for Chai, and experimental validation is required for any computational successes achieved by the Chai-2 model; and although the focus of Chai is primarily on biologics, Chai also develops models for small molecule design.

There is no public free trial or sandbox for Chai; and the access to Chai appears to be restricted to strategic pharma partners after a period of time for evaluating Chai's models.

Is Chai Discovery Worth It?

Chai Discovery represents the cutting edge in AI for biologics design, and Chai-2 has demonstrated unprecedented levels of success for computational-to-experimental results for antibody engineering for previously intractable targets.

Recommended For

  • With backing of $230 million in funding and validation through the Eli Lily partnership, Chai positions large pharma companies to significantly reduce the timelines for discovering new biologics. However, the enterprise-only model for Chai limits the access to Chai for smaller companies.
  • Organizations with a large budget to create custom AI models for biotech companies
  • Companies that are developing monoclonal antibodies and proteins
  • Companies that are focused on computational design and have high experimental hit rates

!
Use With Caution

  • Mid-sized biotechnology companies that do not have a relationship with an enterprise
  • Small molecule discovery companies — only focus on biologics
  • Companies that need access to a publicly available API
  • Teams without resources to validate models through experimentation

Not Recommended For

  • Academic researchers and start-ups looking for affordable tools
  • Small molecule drug discovery companies
  • Companies that require SaaS based solutions that can be easily deployed
  • Teams with limited budgets and no strategic partnership
Expert's Conclusion

Although Chai Discovery is effective for a well-funded pharmaceutical company to accelerate their biologics discovery efforts, it is inaccessible to most due to its enterprise-only deployment.

Best For
With backing of $230 million in funding and validation through the Eli Lily partnership, Chai positions large pharma companies to significantly reduce the timelines for discovering new biologics. However, the enterprise-only model for Chai limits the access to Chai for smaller companies.Organizations with a large budget to create custom AI models for biotech companiesCompanies that are developing monoclonal antibodies and proteins

What do expert reviews and research say about Chai Discovery?

Key Findings

Chai Discovery was founded in 2024 and has developed frontier AI to aid in biologics design; with Chai-2 demonstrating >85% of antibodies created had drug-like properties when targeting previously undruggable targets. Chai Discovery received $230 million dollars of funding at a $1.3 billion dollar valuation after receiving collaboration from Eli Lilly, which validated the platform for use as an enterprise solution. The team from OpenAI/Meta FAIR will develop customized architectures to transform biology into engineering.

Data Quality

Fair - comprehensive press coverage and investor announcements, but limited technical details, no public documentation/pricing, and enterprise-only access hides operational specifics.

Risk Factors

!
Company is very new (founded in 2024).
!
Limiting the availability of the platform to only enterprises limits the ability to test and validate the product within the marketplace.
!
Hit rate of experiments must occur after computation.
!
Highly competitive AI-based biotech industry.
!
There is no public API or SaaS offering from Chai Discovery.
Last updated: February 2026

What Additional Information Is Available for Chai Discovery?

Key Partnerships

Collaboration with Eli Lilly to deploy Chai’s biologics discovery platform across multiple targets, includes a custom AI model trained exclusively on Lilly’s proprietary data.

Recent Funding

Received $130 million dollar Series B round of funding in December 2025 led by Oak HC/FT and General Catalyst, valued company at $1.3B. In total, Chai Discovery has raised $230 million dollars in funding with investors including OpenAI, Thrive Capital, and Menlo Ventures.

Founder Team

Founded by experts from OpenAI, Meta FAIR, Stripe, and Google X. CEO Josh Meier stated that the company is focused on developing the frontier of models to push the boundaries of biological engineering.

Technical Achievements

The Company has demonstrated 85% + drug-like characteristics of antibodies and is a success in developing GPCR agonists/peptide MHC targets which have been considered undrugable.

Media Coverage

The company was featured in TechCrunch, Biospace, and Fierce Biotech regarding its rapid growth since it’s inception as an OpenAI project and now is partnered with Lilly. Investor statements highlight potential for clinical trials in 2027.

What Are the Best Alternatives to Chai Discovery?

  • •
    Recursion Pharmaceuticals: An AI-powered drug discovery platform that maps biological-disease relationships through the lens of various modalities. A broader scope for small molecule/biologics applications with clinical assets vs Chai’s biologics-focused platform. Best suited for integrated discovery-to-clinical pipelines. (recursion.com)
  • •
    Generate:Biomedicines: A generative AI for the design of protein therapeutics with several clinical programs underway. A more developed pipeline than Chai; however, there is less of an emphasis on undruggable targets at the forefront. Best suited for de novo protein engineering. (generatebiomedicines.com)
  • •
    Xaira Therapeutics: An AI-native drug discovery platform supported by over $1 billion in funding focused on novel targets/modalities. Has similar enterprise-scale to Chai but with a broader focus on therapeutics. Best for comprehensive AI drug platforms. (xaira.com)
  • •
    Insilico Medicine: End-to-end AI drug discovery for clinical small molecules using generative AI. A focus on small molecules sets this platform apart from Chai’s biologics platform; an established pipeline. Best for rapid development of small molecule programs. (insilico.com)
  • •
    AbCellera: An AI-based antibody discovery platform that utilizes natural immune repertoire screening. While both Chai and AbCellera utilize AI, the latter combines AI with experimental validation of results versus Chai’s computational-first approach. Best for therapeutic antibody discovery. (abcellera.com)

Scientific ROI Metrics

15.5-20% %
Antibody Hit Rate (Zero-Shot)
100x fold increase
Hit Rate vs Prior Computational Methods
85% %
Drug-Like Properties Success Rate
weeks vs months
Discovery Timeline Reduction
Minimal screening required
GPCR Agonist Generation Efficiency

Core Discovery Capabilities

Zero-Shot Antibody Design

Chai-2 produces full-length monoclonal antibodies with experimental hit rates > 10X and drug-like characteristics.

De Novo Biologics Generation

Produces novel binders for 52 targets with an average hit rate of 15.5 % across formats.

Hard-to-Drug Target Design

Successfully addresses undruggable targets such as functional GPCR agonists and peptide MHC discrimination.

Drug-Like Property Prediction

Achieves success rates of > 85% in all key metrics including thermostability, polyreactivity, self-interaction, hydrophobicity, expression, and purity.

Custom Model Training

Proprietary pharma datasets are used to train purpose-built AI models for workflow integration

Molecular Interaction Prediction

Frontier AI uses prediction and reprogramming of biochemical molecular interaction

Multi-Target Antibody Campaigns

Frontier AI designs antibodies that are successful in targeting multiple disease biomarkers simultaneously

Developability Optimization

Frontier AI's Antibody Design Optimization enables antibodies that match efficacy and safety of approved therapeutics for multiple important drug targets

ML Architecture & Computational Specifications

Core Model
Chai-2 (custom generative architecture, zero-shot antibody design)
Previous Models
Chai-1 (molecular structure prediction matching industry leaders)
Architecture Type
Homegrown generative models (no off-the-shelf LLMs)
Hit Rate Performance
15.5-20% experimental validation across 52 targets
Design Speed
Full campaigns completed in weeks vs months
Target Capabilities
Monoclonal antibodies, GPCR agonists, peptide MHC discrimination
Developability Metrics
85%+ pass rate on thermostability, expression, aggregation, humanness
Training Approach
Proprietary datasets + custom pharma data fine-tuning
Deployment Model
Cloud platform + custom on-premises model training
Molecular Formats
Full-length antibodies, multiple formats supported

What Primary Use Cases Does Chai Discovery Offer?

Zero-Shot Antibody Design (15-20% hit rates)De Novo Biologics GenerationHard-to-Drug Target Enablement (GPCRs)Drug-Like Property OptimizationMulti-Target Antibody CampaignsCustom Model Training for Pharma WorkflowsUndruggable Target DruggingRapid Biologics Discovery (weeks vs months)Developability Prediction & FilteringPeptide MHC Discrimination

What Is Chai Discovery's Regulatory Compliance Requirements Status?

Experimental Validation DocumentationDouble-digit hit rates confirmed experimentally across 52 targets
Proprietary Data IsolationCustom models trained exclusively on client proprietary data
Model Performance Reproducibility85%+ drug-like properties consistently achieved
FDA Submission ReadinessEli Lilly collaboration validates platform for pharma deployment
IP Protection for Generated MoleculesDe novo designs enable novel IP generation
Data Security (Pharma Collaboration)Enterprise-grade security for Lilly proprietary data
Audit Trail for Model DesignsProduction-ready tracking established
GLP Compliance AlignmentPreclinical validation workflows supported
SOC 2 Type II CertificationEnterprise pharma requirements
Model ExplainabilityGenerative architecture transparency developing

Integration & Workflow Capabilities

Pharma Enterprise Deployment

Eli Lilly is using the Frontier AI platform for multiple target areas.

Custom Model Training

The purpose built models are trained on a large amount of proprietary pharmaceutical data.

Discovery Workflow Tailoring

Frontier AI customizes models to each clients process and specific discovery needs.

Platform API Access

Frontier AI has created an enterprise version of the AI platform available to all pharma companies.

Multi-Target Campaign Support

Successful execution of 52 targeted antibody design campaigns have been completed.

Experimental Feedback Integration

Double digit hit rates are validation that the models used in Frontier AI correlate to results from laboratory experiments.

Biologics-Focused Pipelines

Frontier AI creates full length antibodies from a disease biomarker target through to a lead candidate antibody

Cloud Platform Delivery

Frontier AI has developed a scalable version of the platform that can be deployed at the scale required by pharmaceutical company computational resources.

AI Drug Discovery Platform Performance Benchmarks

Performance MetricChai Discovery (Chai-2)Traditional/Previous MethodsImprovement Factor
Antibody Hit Rate15.5-20%0.1-0.2%100x Better
Drug-Like Properties Success85%+Baseline empiricalUnprecedented
52-Target Campaign TimelineFew weeksMonths-years10x+ Faster
GPCR Agonist GenerationMinimal screeningExtensive screeningOrder of magnitude reduction
Undruggable Target SuccessDemonstratedHistorically intractableParadigm shift
Developability MetricsComparable to approvedVariable empirical resultsProduction-grade
Design Success Rate (50% targets)≥1 hit per targetLow single digits5-10x Better
Zero-Shot CapabilityFull-length mAbsLimited scopeFirst of kind

AI Drug Discovery Platform Evaluation Priority Matrix

Priority LevelEvaluation CategoryKey Assessment Questions
1 - CRITICALExperimental Hit Rates15-20% validated success rates? 100x improvement over baselines confirmed?
1 - CRITICALDrug-Like Properties85%+ developability across thermostability, aggregation, expression metrics?
2 - HIGHUndruggable Target PerformanceGPCR agonists, MHC discrimination demonstrated? Hard targets enabled?
2 - HIGHPharma ValidationEli Lilly-scale enterprise deployment? Custom model success?
3 - MEDIUMDe Novo Design CapabilityZero-shot full-length antibodies? 52-target campaign execution?
3 - MEDIUMTimeline CompressionWeeks vs months validated? Production workflow acceleration?
4 - MEDIUMCustom Model TrainingProprietary data integration? Client-specific tailoring?
5 - LOWERArchitecture TransparencyHomegrown generative models? No off-the-shelf dependencies?

Expert Reviews

📝

No reviews yet

Be the first to review Chai Discovery!

Write a Review

Similar Products

PostEra
postera.ai
BenevolentAI
benevolent.ai
Recursion Pharmaceuticals
recursion.com